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Circulating B lymphocytes producing
autoantibodies to endothelial cells play a role in
the pathogenesis of Takayasu arteritis
Haitao Wang, MD, Jun Ma, MD, Qinghua Wu, MD, Xiaoyun Luo, MD, Zhong Chen, MD, and
Lei Kou, MD, Beijing, China
Objective: Takayasu arteritis (TA) is an autoimmune disease with an unclear etiology and pathophysiology. An antibody-
mediated inflammatory response is a known feature of this disease, however, the role of circulating B-lymphocyte production
of such antibodies is not known. The objective of this study is to characterize in vitro production of autoimmune antibodies
by B-lymphocytes from patients with TA and to examine differences related to disease activity.
Methods: Peripheral blood samples were taken from 72 patients with TA and 50 age-matched controls. Among the patients
with TA, 42 had active disease while 31 had inactive disease. The Sharma modified criteria were used for diagnosis, and
the National Institutes of Health criteria were used for TA activity assessment. Levels of autoantibodies in culture
supernatant of circulating B-lymphocytes, including anti-endothelial cell antibody (AECA), anti-cardiolipin antibody
(ACA), anti-beta2 glycoprotein-I antibody (a2GPI), and anti-annexin V antibody (AAVA), were assayed by enzyme-
linked immunosorbent assay (ELISA) in each participant.
Results: In vitro levels of AECA, ACA, a2GPI, and AAVA from circulating B-lymphocytes were significantly increased
in TA patients compared with controls (AECA: 0.6 0.36 vs 0.18 0.09, P< .001; ACA: 0.69 0.22 vs 0.54 0.13,
P < .001; a2GPI: 0.99  0.19 vs 0.83  0.07, P< .001; AAVA: 0.62  0.26 vs 0.41  0.44, P < .001). In vitro levels
of AECA, ACA, and AAVA from circulating B-lymphocytes in active TA were higher than those in inactive TA (AECA:
0.85 0.29 vs 0.28 0.10, P< .001; ACA: 0.79 0.21 vs 0.56 0.15, P< .001; AAVA: 0.82 0.16 vs 0.36 0.06,
P < .001). No difference was found in the in vitro level of a2GPI between active TA and inactive TA (1.01  0.17 vs
0.96 0.22, P .115). In vitro levels of AECA, ACA, and AAVA from circulating B-lymphocytes in inactive TA showed
no statistic difference with those in controls (AECA: 0.28  0.10 vs 0.18  0.09, P  .096; ACA: 0.56  0.15 vs 0.54
 0.13, P  .699; AAVA: 0.36  0.06 vs 0.41  0.44, P  .200). In vitro levels of a2GPI in inactive TA were higher
than those in controls (0.96  0.22 vs 0.83  0.07, P < .001).
Conclusions: This study characterizes in vitro production of autoantibodies by circulating B-lymphocytes from patients
with TA. Differences in production from those with active versus inactive disease suggest that phenotypic alterations in
this cell type may play an important role in pathogenesis. ( J Vasc Surg 2011;53:174-80.)
Clinical Relevance: Takayasu arteritis (TA) is a rare and autoimmune vasculitis with unclear pathogenesis. It has a high
incidence in young females in Asia and Africa. The natural course of TA consists of an active phase and an inactive phase,
which reflects the different inflammatory states of the arterial lesions. In the active phase, immunosuppressive and
cytotoxic agents are usually used to control the inflammation development, release the symptoms, and restrict the extent
of affected arteries. The treatment aim of the inactive phase is to avoid the disease activity, and if necessary, it is preferable
to perform vascular reconstructive operations or endovascular interventions. It is very important that an effective therapy
should be found to shorten the active phase of TA and lengthen the inactive stage, which can not only perform the surgery
operation as early as possible, but also reduce inflammatory injury of arteries. In recent years, we have been working on
the diagnosis and surgical treatment of TA.Our advance study, “Circulation levels of acute phase proteins in patients with
Takayasu arteritis” published in “J Vasc Surg 2010;51:700-6”, contributed to the judgment of disease phase and showed
the pivotal role of B cells and humoral immunity in TA.
In this study, we found that circulating B-lymphocytes, producing autoantibodies to endothelial cells, played an
important role in the pathogenesis of TA. It means that part/all of the circulating B-lymphocytes in TA patients can be
activated and excrete autoantibodies to endothelial cells. If these abnormal circulating B-lymphocytes can be differenti-
ated and separated from peripheral blood, the active phase could be shorten, the inactive stage could be lengthened, the
disease could even be prevented. It might lessen the autoimmune injury of artery wall, lower the difficulty of the operation
and shorten the time which TA patients should wait for vascular reconstructive operations or endovascular repair.
Therefore, we regarded this study as a foundation of B-cell depletion therapy and/or immunological tolerance therapy
for TA. The feasible therapeutic methods will be explored in our future research.
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Volume 53, Number 1 Wang et al 175Takayasu arteritis (TA) is a rare, idiopathic chronic
inflammatory vasculitis that mainly causes stenosis and/or
aneurysm formation of large elastic arteries, such as the
aorta and its primary branches, pulmonary, and coronary
arteries.1 It has a high incidence in young females in Asia
and Africa. Potential etiology includes infectious agents,
genetic factors, and autoimmunity.2
The lesion caused by inflammation is a chronic arteritis
with lymphocyte and polymorphonuclear cell infiltration,
fibrosis, and fragmentation of elastic fiber. The natural
course of TA consists of an active phase and an inactive
phase, which reflects the different inflammatory states of
the arterial lesions.3,4
Immune-mediated damage of vascular endothelial cells
(ECs) is the initial event in the physiopathology of TA. The
presence of complement-dependent cytotoxicity (CDC),
antibody-dependent cell cytotoxicity (ADCC) to ECs and
ECs apoptosis in vascular lesions suggests that autoanti-
bodies may be one of the major pathways of inflammatory
damage of ECs.4,5 Actually, varied kinds of autoantibodies
to ECs have been detected in TA patients’ peripheral blood
and lymph tissue, such as anti-endothelial cell antibodies
(AECAs), antiphospholipid antibodies (aPLs), and anti-
annexin antibodies (aANAs). Therefore, TA is mostly con-
sidered an autoimmune disease.6-8
Little is known about the regulatorymechanisms involved
in the generation of these autoantibodies. The production of
autoantibodies mainly results from abnormal B-cell activation
that reflects appositive selection of autoantibody-secreting
cells.9,10 Studies have shown that circulating B-lymphocytes
could be activated and produce autoantibodies. The defective
immune tolerance checkpoint and the activated B-lymphocytes
in the periphery may explain the existence of autoantibod-
ies in TA patients’ blood.11,12 Therefore, we speculate that
the circulating B-lymphocytes producing autoantibodies
contribute to the genesis and progression of TA. The
objective of this study is to characterize in vitro production
of autoimmune antibodies from circulating B-lymphocytes
drawn from patients with TA. Additionally, the objective of
this study is to examine differences in antibody production
related to the active and inactive forms of disease.
METHODS
Patients and controls
A total of 73 patients with TA (mean age, 30.68 
11.07 years; range, 11-65 years) referred to the Vascular
Surgery Out-Patient Department of Anzhen Hospital affil-
iated to the Capital Medical University of China were
studied.
The diagnosis of all the patients firmly abided by the
Sharma modified criteria for TA.13 The exclusion criteria
for this study are as follows: (1) in the process of medical
immunosuppressive therapies or received one in the last 14
days; (2) history of autoimmune disease such as systemic
lupus erythematosus (SLE) or rheumatoid arthritis (RA);
(3) history of trauma or surgical operation within 1 month;
(4) history of cardiovascular or cerebrovascular event (eg,myocardial infarction or stroke); and (5) acute or chronic
inflammatory conditions such as acute bacterial or viral
infection and chronic inflammatory bowel disease.
TheNational InstituteHealth (NIH) criteria were used
to evaluate the activity of TA in this study.14 Patients who
had the onset or worsening of any of the four features
described below, received 1 point per feature in the scoring
system. Subjects who had a total score of 2-4 were classified
as being in the active phase, while those with a total score of
0 or 1 were classified as being in the inactive or quiescent
phase of TA. The four feature are: (1) presence of systemic
features such as fever or musculoskeletal problems (no
other cause identified); (2) elevated erythrocyte sedimen-
tation rate (ESR); (3) presence of features of vascular
ischemia or inflammation, such as claudication, diminished
or absent pulse, bruits, vascular pain, or asymmetrical blood
pressure in either upper or lower limbs; and (4) typical
angiographic features. The vascular lesions of each subject
who was suspected in an active phase of disease were
examined by angiography or computerized tomography
angiogram (CTA). In inactive patients, the absence of new
vascular lesions was verified by ultrasonography, CTA, or
magnetic resonance angiography (MRA). According to the
criteria, 42 patients were in the active phase and 31 patients
were in the inactive phase in this study.
The angiographic features were classified according to
the angiographic classification of the international TA con-
ference held in Tokyo in 1994 as follows: type I, involve-
ment of the main branches from the aortic arch; type IIa,
involvement of the ascending aorta, aortic arch, and its
branches; type IIb, involvement of the ascending aorta, aortic
arch and its branches, and thoracic descending aorta; type III,
involvement of the thoracic descending aorta, abdominal
aorta, and/or renal arteries; type IV, involvement of the
abdominal aorta and/or renal arteries; and type V, the
combined features of type IIb and IV.15,16
The control group consisted of 50 age- and gender-
matched healthy volunteers (mean age, 30.92 9.71 years;
range: 14-65 years) without a history of cardiovascular
disease, collagen disease, autoimmune disease, and current
inflammatory state. The study protocol firmly conformed
to the guidelines of the Declaration of Helsinki and the
Ethics Board of the Capital Medical University, Beijing,
China.
Cell preparation
B-cell purification. After informed consent, 10 mL of
peripheral blood was collected from each subject’s medial
cubital vein; the subjects fasted in morning. Subsequently,
peripheral blood mononuclear cells (PBMNC) were iso-
lated by Ficoll-Hypaque (Lymphoprep; Haoyang Biologi-
cals Technology Co Ltd, Tianjin, China) density gradient
centrifugation. Circulating B-lymphocytes were purified by
positive selection with anti-CD19 mAb-coated immun-
emagnetic beads (Miltenyi Biotec GmbH, Bergisch Glad-
bach, Germany), then anti-CDl9 mAb was removed by use
of Detach-a-Bead (Dynal Biotech, Oslo, Norway).
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Coulter Inc, Miami, Fla) was used to assay the purity of B
cells in samples. Cells were stained with phycoerythrin (PE)
conjugated anti-CD19 mAb (Santa Cruz Biotechnology
Inc., Santa Cruz, Calif). The purity and viability were both
95%.
B-cell culture. Highly purified B cells were cultured in
RPMI-1640 medium supplemented with 10% heat-inactivated
fetal calf serum, in the presence of 50 U/mL of IL-2, 100
ng/mL of IL-10, and 5 g/mL of pokeweed mitogen
(PWM) (Haoyang Biologicals Technology Co. Ltd, Tian-
jin, China) at a final cell density of 2  105/mL in 1-
mL/well in 24-well round-bottom plates for 10 days at
37°C in a humidified atmosphere with 5% CO2. The cul-
tured supernatants were harvested and stored at80°C for
future use.
Endothelial cell culture. Human umbilical vein en-
dothelial cells (HUVECs), EA.hy 926 cells (ATCC: CRL-
2922, Manassas, Va), were cultured in RPMI-1640 me-
dium supplemented with 15% FCS at 37°C in an
atmosphere of 5% CO2. Normal HUVECs showed cobble-
stone appearance, positive for von Willebrand factor
(vWF). HUVECs under the fourth subpassage were used as
the substrates of enzyme-linked immunosorbent assay
(ELISA) for AECAs.
Biochemical laboratory investigations
Biochemical investigation was performed, including
hemogram and blood biochemistry test. ESR was assayed
by the Westergren method.
AECAs ELISA
Cell ELISA was performed for detection of anti-endothelial
cell antibodies (AECAs). HUVECs harvested previously
were plated in 96-well collagen-coated microtiter plates
(JHDLAB, Guangdong, China) and allowed to grow for
72 hours, 5 105 in each well. After three washes with 1%
Tween phosphate buffer solution (Tween-PBS), the cells
were fixed with 0.1% glutaraldehyde and 0.5% Triton
X-100 for 15 minutes at 4°C. Nonspecific binding sites
were blocked for 2 hours at room temperature with 1%
bovine serum albumin (BSA)/PBS. After three washes with
PBS, the wells were perfused in quintuplicate with 100Lof
Table I. Clinical characteristics of the participants
Demographics Active TA (n  42) In
Age, mean  SD, y 29.9510.62
Female/male 37:5
Vessel involvement, No. (%)
Type I 17 (23.3)
Type IIa 3 (4.1)
Type IIb 1 (1.4)
Type III 3 (4.1)
Type IV 4 (5.6)
Type V 14 (19.2)
SD, Standard deviation; TA, Takayasu arteritis.the B-cell culture supernatants diluted 1:40 in BSA/PBS for90 min at 37°C. After five washes with 1% Tween-PBS,
100-L horseradish peroxidase-conjugated rabbit anti-hu-
man IgG antibodies (LifeSpan BioSciences, Seattle, Wash)
were used to detect the bound antibodies on HUVECs of
using 4 mg/mL p-nitrophenyl phosphate. Optical density
(OD) value was measured at 450 nm in a Thermo Multi-
skan III (Thermo Labsystems, Helsiniki, Finland). Three
standard positive and negative controls were included in
each plate. Each plate was read when the OD of positive
controls reached 1.5-1.8 (always within 35 minutes). The
blank value of the plate was subtracted from the sample
value to obtain OD for each sample. Results were expressed
as ELISA ratio (ER) calculated as ER  (S-A)/(B-A),
where S is the OD of the sample, and A and B are ODs of
standard negative and positive controls. ER values greater
than the mean 3 standard deviation (SD) values in the
normal control were considered positive.
Analysis of other autoantibodies to ECs
Autoantibodies in B-cells culture supernatants including
anti-cardiolipin antibody (ACA), anti-beta2 glycoprotein-I
antibody (a2GPI), and anti-annexin V antibody (AAVA)
were measured by ELISA using a commercially available
ELISA kit according to the manufacturer’s instructions.
Total ACA Screen ELISA Kits (Genesis Diagnostics Ltd,
Cambridgeshire, UK) were used to assay ACA levels. Beta2
glycoprotein I IgG ELISA Kits (GD31, Genesis Diagnos-
tics Ltd, Cambridgeshire, UK) were used to assay a2GPI
levels. Human anti-Annexin V ELISA Kits (BMS247;
Bender MedSystems GmbH, Vienna, Austria) were used to
assay AAVAs levels. The results, OD values, were expressed
as mean  SD.
Statistical analysis
Analysis of variance (ANOVA) and least significant
difference (LSD) tests, and Fisher exact probability tests
were appropriately used to compare the differences be-
tween the groups. The analysis was conducted with
SPSS18.0 software (SPSS Inc, Chicago, Ill). Two-tailed P
	 .05 were considered significant.
RESULTS
The clinical characteristics of participants are shown in
TA (n  31) Total TA (n  73) Controls (n  50)
4  11.46 30.68  11.07 30.92  9.71
28:3 65:8 44:6
(15.1) 28 (38.4) None
(2.8) 5 (6.9) None
(0) 1 (1.4) None
(2.8) 5 (6.9) None
(2.8) 6 (8.4) None
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phase, which were divided in three groups according to
diagnosis and activity phasing criterions. Mean ages of the
active-phase TA, inactive-phase TA, and the control group
were 29.95  10.62, 32.84  11.46, and 30.92  9.71
years, respectively (P  .322). The female/male ratios of
active TA, inactive TA, and controls were 7.4:1, 9.3:1, and
7.3:1, respectively (P  .533). According to angiographic
classification data, type I (28/73) and type V (28/73) were
the most common in the TA group. There was no statistical
difference in angiographic classification between active TA
and inactive TA.
Results of biochemical investigations are shown in Ta-
ble II. ESR in active-phase patients was more frequently
elevated than that in inactive-phase patients (95.2% vs
16.1%). The mean ESR was 48.24 20.45mm/h in active
TA compared with 12.23  7.21 mm/h in inactive TA
(P	 .001) and 8.58 4.73 mm/h in controls (P	 .001).
However, hemoglobin levels in the active and inactive
groups were lower than that in the control groups (99.02
11.36 g/L and 101.9  12.33 g/L vs 120.70  11.26
g/L; both P 	 .001). No distinction was found in other
biochemical data between groups.
AECAs ELISA. Samples of 73 TA patients and 50
controls were assayed by cell ELISA. The positive number
and percentage are shown in Table III. ER values are shown
in Fig 1. AECAs were present in culture supernatant of
Table II. Results of laboratory biochemical investigations
Investigations Active TA (n  42) I
ESR, mm/h 48.24  20.45a,b
Hemoglobin, g/L 99.02  11.36a
White blood cells, 109/L 8.56  1.58
Platelets, 109/L 204.98  35.67
ALT, U/L 21.36  7.15
Fasting blood glucose, mmol/L 5.34  1.35
Urea, mmol/L 5.59  0.77
Creatinine, mol/L 96.01  16.98
Total cholesterol, mmol/L 5.07  0.59
Triglyceride, mmol/L 0.79  0.47
LDL, mmol/L 2.44  0.85
ALT, Alanine aminotransferase; ESR, erythrocyte sedimentation rate; LDL,
aP 	 .05 vs control group.
bP 	 .05 vs inactive TA group.
Table III. Frequencies of AECA in patients with TA
detected by ELISA
Frequencies of AECA, No. (%)
Positive Negative
Active TA (n  42) 36 (85.75) 7 (14.25)
Inactive TA (n  31) 5 (16.13) 26 (84.87)
Total TA (n  73) 41 (56.16) 33 (43.84)
Controls (n  50) 0 (0) 50 (100)
AECA, Anti-endothelial cell antibody; ELISA, enzyme-linked immunosor-
bent assay, TA, Takayasu arteritis.circulating B-lymphocytes in 41 of the 73 patients with TA(56.16%), including 36 of the 42 patients (85.75%) in the
active group and 5 of the 31 patients (15.13%) in the
inactive group. There was a significant difference between
the positive frequencies of AECAs in these two subgroups
of TA patients. None of the ER values in any of the 50
controls was higher than the mean3SD values in the
normal controls. As shown in Fig 1, the in vitro levels of
AECAs from circulating B-lymphocytes in TA patients
were significantly higher than those in the controls (0.6 
0.36 vs 0.18 0.09; P	 .001). The levels of AECAs were
significantly higher in culture supernatant of circulating
B-lymphocytes from active patients than those from inac-
an  SD)
ve TA (n  31) Total TA (n  73) Controls (n  50)
.23  7.21 32.95  24.11a 8.58  4.73
1.9  12.33a 110.25  11.79a 120.70  11.26
.56  1.58 8.72  1.61 7.19  1.28
.27  30.88 204.27  33.50 206.36  26.45
0.1  8.54 20.82  7.74 18.4  6.54
.28  0.93 5.31  1.18 5.05  0.57
.37  0.92 5.49  0.84 5.47  0.8
.89  17.27 74.69  17.06 75.52  22.6
.95  0.73 5.02  0.65 5.11  0.67
.01  0.48 0.87  0.48 0.91  0.59
.10  0.35 2.30  0.70 2.24  0.65
ensity lipoprotein; SD, standard deviation; TA, Takayasu arteritis.
Fig 1. Enzyme-linked immunosorbent assay (ELISA) ratio (ER)
values of cell ELISA in a total of 73 Takayasu arteritis (TA)
patients, including 42 active-phase patients, 31 inactive-phase TA
patients, and 50 healthy controls. The level in TA patients was
significantly higher than that in healthy controls (0.6  0.36 vs
0.18  0.09; P 	 .001). The level was significantly higher in the
active group than in the inactive group (0.85  0.29 vs 0.28 
0.10; P 	 .001). There was no significant difference between the
inactive group and the healthy controls (0.28  0.10 vs 0.18 
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controls (0.28  0.10 vs 0.18  0.09; P  .096).
Autoantibodies to ECs ELISA. This study analyzed
three autoantibodies to ECs, including ACA, a2GPI, and
AAVA. The data were normally distributed and tested by
Kolmogorov-Smirnov test. The in vitro levels of these three
autoantibodies are shown as mean  SD in Table IV,
together with the positive frequencies of each group. Com-
parison among the groups of these three autoantibodies is
shown in Fig 2.
Levels of ACA in culture supernatant of circulating
B-lymphocytes were significantly higher in patients with
active TA than patients with inactive TA and the controls
(0.79  0.21 vs 0.56  0.15; P 	 .001 and 0.54  0.13;
P 	 .001, respectively). There was no statistical difference
between inactive TA patients and the controls (P  .699).
A significant elevation of a2GPI levels was observed in
Table IV. Levels of autoantibodies to ECs
Autoantibody lev
Autoantibodies Active TA (n  42) Inactive
ACA 0.79  0.21, 26 (61.9)a,b 0.56  0.1
a2GPI 1.01  0.17, 30 (71.4) 0.96  0.2
AAVA 0.82  0.16, 42 (100)a,b 0.36  0.0
AAVA, Anti-annexin V antibodies;ACA, anti-cardiolipin antibody; a2GPI
Unless otherwise indicated, OD values are expressed as mean  standard d
aP 	.01 vs inactive TA group.
bP 	 .01 vs control group.
Fig 2. Level of anti-cardiolipin antibody (ACA) was sig
and in controls (0.79 0.21 vs 0.56 0.15; P	 .001 an
difference between the inactive Takayasu arteritis (TA)
significantly higher in the TA group than in the contro
significant difference between the active group and the
(AAVA) was significantly higher in the active group than
0.06; P	 .001 and 0.41 0.04; P	 .001, respectively).
and the control (P  .200).culture supernatant of circulating B-lymphocytes from TApatients compared with the controls (0.99  0.19 vs
0.83  0.07; P 	 .001). No significant difference was
detected between the active group and the inactive group
(P  .155). A statistical difference was found between
inactive TA patients and the controls (0.96  0.22 vs
0.83  0.07, P 	 .001).
We also found a significant elevation of AAVA levels in
culture supernatant of circulating B-lymphocytes from active
TA comparedwith inactive TA and the controls (0.82 0.16
vs 0.36  0.06; P 	 .001 and 0.41  0.04, P 	 .001;
respectively). No statistical difference was found between
the inactive group and the control group (P  .200).
DISCUSSION
The etiology and the pathophysiology of TA remain
unclear. The injury of vascular endothelium, the infiltration
of lymphocytes and monocytes in three layers of arterial
D value), positive frequencies (No., %)
 31) Total TA (n  73) Controls (n  50)
(19.4) 0.69  0.22, 32 (43.8)b 0.54  0.13, 3 (6)
(58.1)b 0.99  0.19, 48 (65.8)b 0.83  0.07, 1 (2)
(0) 0.62  0.26, 42 (57.5)b 0.41  0.04, 0 (0)
beta2 glycoprotein-I antibody; ECs, endothelial cells; TA, Takayasu arteritis
n.
ntly higher in the active group than in the inactive group
 0.13; P	 .001, respectively). There was no statistical
nts and the controls (P  .699). Level of a2GPI was
99  0.19 vs 0.83  0.07; P 	 .001). There was no
ve group (P 	 .155). Level of anti-annexin V antibody
e inactive group and the control (0.82 0.16 vs 0.36












Therwall, the existence of various cytokines, and autoantibodies
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especially in the active phase.17 The predominant alter-
ations in the inactive phase are degradation of the elastic
layer and fibrosis of the adventitia and media. Most patients
with TA experience one or several cycles from the active
phase to remission, then, relapse. The two terms, active and
inactive, show different inflammatory states on the arterial
wall. Immunosuppressive therapies are designed to induce
remission in the active phase, while surgery operations
manage the ischemic complications of inactive patients. In
advanced studies, we first evaluated circulation levels of
acute phase proteins in TA patients and defined their pos-
sibility as biomarkers for activity judgment in this disease.18
It is also suggested that humoral immunity functional
disorder exists in TA patients. Various studies have indi-
cated that TA had a tight relationship with autoimmunity
mechanism. The basic pathologic mechanism is damage of
vascular endothelium induced by autoantibodies.19-21 Au-
toimmunity is viewed as a defect of either B or T lympho-
cyte selection, with aberrant lymphocytic and autoantibod-
ies responses to autoantigens.10,21 It has been amply
demonstrated that B cells play critical initiating and/or
amplifying pathogenic roles in a wide variety of autoim-
mune diseases, such as SLE, idiopathic autoimmune
thrombocytopenia, and dermatomyositis. The onset and
remission of autoimmune disease depended on the physio-
logic balance between B cell pathogenic and protective
functions.12 As is known, B cells with some degree of
autoreactivity, producing autoantibodies, are extremely
common in the primary central immune organ of humans.
Under the normal physiologic conditions, a series of effec-
tive censoring mechanisms performed throughout the de-
velopment and regulation of B cells. Those abnormal cir-
culating B-lymphocytes, which either escape earlier screen
in the central immune organ or are generated anew from
mature B cells, can cause excessive immune response and
autoimmune disease.22-25 Therefore, the existence of mul-
tiple kinds of autoantibodies, CDC, and ADCC in autoim-
mune disease patients strongly suggested that numerous
exceptional circulating B-lymphocytes play a crucial role in
the pathogenesis of these diseases. It has been found that
defective B cells tolerance check points in the periphery
accounting for the diversity of autoantibodies reflect a
positive selection of autoantibody-secreting cells in circula-
tion of SLE patients.26,27 As a kind of autoimmune disease,
it is possible to be a key factor in the pathogenesis of TA
that the abnormal B cells exist and produce autoantibodies
in peripheral blood. The current study purified and cul-
tured circulating B-lymphocytes separated from the blood
of patients with TA and assayed levels of specific anti-
endothelial cell antibodies. Findings from this study dem-
onstrate that phenotypic and/or functional alterations of
circulating B-lymphocytes occurred in TA patients.
The clinical data of the 42 active-phase and 31 inactive-
phase TA patients included in present study showed some
similarities with data from previous reports. The mean age
in our study was 30.68 years in the TA group, and the ratio
of women to men was 8:1, which was similar to the reportsof Korean (6:1) and Mexican (6.9:1) patients, but lower
than that of Japanese (24:1), and higher than that of Indian
(2.1:1) and Thai (2.15:1) patients. In the angiographic
features, type I and type V are more frequent, which
matched the data of Korean, Japanese, and Indian studies.
Laboratory biochemical investigations showed a signif-
icant elevation of ESR and slight anemia in TA patients.
Other indexes were within normal limits. Multiple autoan-
tibodies found in the circulation of TA patients may influ-
ence the survival of red blood cells, which may contribute
to the anemia found in TA patients. ESR level was signifi-
cantly elevated in TA patients, especially in the active-phase
patients, which showed similar results with other reports.28
We should not ignore that the participants were assessed
and grouped by the NIH criteria, in which an elevation of
ESR is considered a criterion.
In most autoantibody examinations, blood serum was
served as a testing sample. Massive immunocytes and in-
flammatory factors, which could influence activity and sur-
vival time of antibodies in circulation, might contribute to
the various results in many studies. In the present study, we
used the culture supernatant of circulating B-lymphocytes
instead of serum to assay AECA, ACA, a2GPI, and AAVA,
which have been respectively proven to have high relevance
with TA in multiple studies. We analyzed the relationship
between the pathogenesis of TA and biologic characteris-
tics of circulating B-lymphocytes by evaluating their ability
of producing these four autoantibodies.
AECAs were defined as a group of heterogeneous
autoantibodies that could conjugate multiple proteins of
ECs in 1970s. They could mediate the damage and apo-
ptosis of ECs and enhance leukocyte adhesion and also
cause vascular inflammation and thrombosis in many auto-
immune diseases, including TA and SLE.29 As a major
autoantibody to phospholipid composition of the member
of ECs, ACAwas first found in 1983. Since then, it has been
described increasingly in several systemic autoimmune dis-
orders, including SLE, anti-phospholipid syndrome (APS),
and TA. It could conjugate cardiolipin binding 2GPI in
member of ECs and mitochondria and then induce ECs
damage.30,31 2GPI, a plasma protein, has been identified
as a cofactor for the binding of ACA to phospholipids. It is
considered as the key factor in the process of ACA perform-
ing its functions. The level of a2GPI was correlated with
the clinical manifestations and compared with the level of
ACA in LSE or APS patients. The examination of a2GPI,
together with ACA, can elevate the sensitivity and accuracy
of diagnosis.32,33 AAVAs were first identified as autoanti-
bodies to annexin V by Matsuda et al in patients with
habitual fetal loss. Annexin V is found abundantly in ECs
and has a Ca2-dependent binding affinity to phosphati-
dylserine (PS).34 It serves as a shield of exposed PS in
apoptotic cells to avoid inflammatory and coagulant activ-
ities. AAVA can competitively inhibit this protective mech-
anism. Recently, AAVA has been described in SLE, APS,
and TA and observed to cause apoptosis of cultured ECs in
vitro.8, 35
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tibodies in culture supernatant demonstrated that the cir-
culating B-lymphocytes of TA patients had a higher ability
of autoantibody production than those in normal people. It
strongly suggested that it might be an important etiologic
agent of TA that autoantibody-secreting B cells abundantly
existed in peripheral blood.
The lower in vitro levels of three autoantibodies in the
inactive group than the levels in the active group indicated
that with the declining ability of autoantibodies= produc-
tion of circulating B-lymphocytes, patients might go into
remission, and the low ability might be an important factor
of maintaining TA inactive. The phenotypic transformation
of these abnormal circulating B-lymphocytes was still un-
clear. However, we speculated that if they could be differ-
entiated and separated from peripheral blood, B-cell deple-
tion therapy might help TA recovery as soon as possible,
even prevent relapse.
In conclusion, we reported the high levels of four
autoantibodies to ECs in culture supernatant of circulating
B-lymphocytes in TA patients, especially in active TA pa-
tients. To our knowledge, this was the first time the high
ability of autoantibody production of circulating B-lympho-
cytes in TA patients was demonstrated. Further research is
needed for the mechanisms of circulating B-lymphocytes
activation and secreting autoantibodies.
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